Page last updated: 2024-12-07

c 29 (contrast media)

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

C 29 (contrast media): structure; do not confuse with C29 which is vedrenan [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID129855
SCHEMBL ID9012617
MeSH IDM0074685

Synonyms (12)

Synonym
isophthalamide, n,n'-bis(2,3-dihydroxypropyl)-5-(n-(2-hydroxyethyl)acetamido)-2,4,6-triiodo-
c 29 (contrast medium)
brn 2406160
1,3-benzenedicarboxamide, 5-(acetyl(2-hydroxyethyl)amino)-n,n'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-
c 29
70894-76-7
5-[acetyl(2-hydroxyethyl)amino]-1-n,3-n-bis(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide
c-29, nonionic contrast medium
c 29 (contrast media)
SCHEMBL9012617
DTXSID80991184
5-[acetyl(2-hydroxyethyl)amino]-n~1~,n~3~-bis(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboximidic acid
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.15

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.15 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.15)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]